Median Technologies has updated its Median LMS (Lesion Management Solution) software toevaluate, follow and report on changes involving of cancerous lesions seen on CT images from the neck to the pelvis.
Median Technologies has updated its Median LMS (Lesion Management Solution) software to
evaluate, follow and report on changes involving of cancerous lesions seen on CT images from the neck to the pelvis. The enhanced software, slated to debut at RSNA 2009, generates a single report for the quantitative management of patient response to therapy, according to the company. It is designed for routine clinical use, as well as in multicenter clinical trials. Median LMS automates the initial evaluation and follow-up of cancerous lesions identified in CT images of the thorax, abdomen and pelvis, automatically generating a standardized oncologic report and centralizing all lesion information. In so doing, it helps in the assessment of patient response to therapy, assisting in an evaluation of the effectiveness drugs. This can be especially important in clinical trials, when experimental drugs require standardized measurement and reporting of target lesion response, according to the company.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
Researchers Show Higher Breast Cancer Upstaging Rate with 18F-FAPI PET/CT
September 9th 2024The imaging agent 18F-FAPI PET/CT demonstrated greater than a 45 percent higher sensitivity rate in comparison to 18F-FDG PET/CT for the detection of axillary and extraaxillary regional lymph node metastases, according to a lesion-based analysis from a recent study.
Study Assesses Lung CT-Based AI Models for Predicting Interstitial Lung Abnormality
September 6th 2024A machine-learning-based model demonstrated an 87 percent area under the curve and a 90 percent specificity rate for predicting interstitial lung abnormality on CT scans, according to new research.